Could vagus nerve stimulation target hippocampal hyperactivity to improve cognition in schizophrenia?

Jason Smucny1,2,3*, Adrienne Visani2 and Jason R. Tregellas1,2,3

1 Neuroscience Program, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2 Research Service, Denver Veterans Affairs Medical Center, Denver, CO, USA
3 Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

*Correspondence: jason.smucny@ucdenver.edu

Edited by:
Joaquim Radau, King’s College London, UK
Reviewed by:
Daniel J. Lodge, University of Texas Health Science Center in San Antonio, USA
Diego Redolar-Ripoll, Open University of Catalonia (UOC), Spain

Keywords: vagus nerve stimulation, schizophrenia patients, hippocampus, cognition, acetylcholine

Despite the fact that cognitive function is the best predictor of functional outcome and quality of life in schizophrenia (1), cognitive symptoms remain poorly treated in the illness. A myriad of cognitive domains are affected, including selective and sustained attention, working memory, episodic memory, processing speed, executive function, and social cognition (2). Patients consequently suffer from high unemployment rates (80%) and most are unable to live independently (30%) (3). Clearly, new treatments are needed.

One strategy for developing new interventions for these symptoms is to focus on treatments that may target biological indicators ("biomarkers") of cognitive dysfunction. Recently, our laboratory found that resting-state hyperactivity of the hippocampus (as examined by functional magnetic resonance imaging) was strongly predictive of poor cognition in schizophrenia patients (4). This finding, along with previous studies that have demonstrated increased hippocampal blood flow (5), blood volume (6, 7), and hyperactivity during sensory processing (8, 9) in the disease suggests that hippocampal hyperactivity may be a biomarker for cognitive dysfunction in the illness (10). Loss of inhibitory signaling in the hippocampus is also hypothesized to play a role in sensory filtering deficits in schizophrenia (11), one of the most prominent electrophysiological features of the disease. This loss is thought to be conveyed through reduced nicotinic (12, 13) and/or GABAergic (14) signaling. It follows that interventions that reduce hippocampal hyperactivity may have therapeutic benefit in schizophrenia.

First developed in the 1980s for epilepsy, vagus nerve stimulation (VNS) may be a promising method for targeting hippocampal hyperactivity and improving cognition in schizophrenia. The vagus nerve (VN) is the longest cranial nerve, extending from the brain to the abdominal cavity. Although the VN is traditionally thought to primarily mediate central nervous system control of parasympathetic function, in actuality the VN consists of 80% afferent signals (from external organs to the brain) and 20% efferent signals (from the brain to organs) (15). VNS is most commonly achieved by surgical implantation of a stimulating, current-carrying wire around the nerve in the neck (16). The wire is intermittently stimulated by a battery-operated generator that is implanted in the left chest wall. Stimulation is directional (going to the brain), minimizing potential side effects from the VN's efferent projections. Stimulus parameters (e.g., stimulus intensity, frequency, and duration) can be programmed by a physician to maximize efficacy. More recently, a non-surgical method of VNS known as transcutanous VNS (t-VNS) has been developed, in which the auricular branch of the VN is stimulated by electrodes placed on the outer ear (17–19). This stimulation site is in close proximity to an acupuncture site that may stimulate the VN in a similar manner (20). Interestingly, a number of studies have shown poor parasympathetic regulation of autonomic function in schizophrenia (21–26), suggesting that hypoactive VN function may contribute to disease pathophysiology.

By using VNS in combination with various functional neuroimaging techniques, researchers have frequently examined how VNS affects human brain activity. One of the most consistent neurophysiological effects of VNS is decreased hippocampal activity, possibly through enhancement of GABAergic signaling (27). As shown in Table 1, decreased hippocampal activity after VNS has been reported in over 15 studies (18, 28–44), although some others have not reported significant effects (45, 46). Remarkably, this effect has been observed in epileptic patients, depressed patients, and healthy subjects, suggesting that VNS may decrease hippocampal activity independent of the pathological state of the subject. Most relevant to schizophrenia, a recent in vivo electrophysiology study using the methylazoxymethanol acetate (MAM) rodent model of schizophrenia found decreased hippocampal hyperactivity in rats after 2 weeks VNS treatment (44). Furthermore, deep brain stimulation-induced reduction of hippocampal hyperactivity improves cognitive flexibility in the MAM rat model (47), suggesting that hyperactivity of the region may be targeted to improve cognition in schizophrenia.

Vagus nerve stimulation also has demonstrated pro-cognitive effects in a number of studies. As reviewed by Vonck et al. (48), improved cognition after VNS has been observed in patients with epilepsy, Alzheimer’s, and depression. Cognitive domains that have shown improvement include verbal recognition, attention, memory consolidation, and executive function (48). Other studies, however, have not shown significant effects, possibly due to changes in stimulus or study parameters (e.g., placebo design) (48). Indeed, studies
that examine the effects of chronic VNS often lack appropriate placebo controls due to ethical issues in applying “placebo” stimulation protocols to patient populations. This concern may be addressed by studies in healthy subjects using non-invasive t-VNS, in which placebo “stimulation” is delivered by an electrode placed on the earlobe (27). Nonetheless, the effects of non-invasive t-VNS on cognitive performance have yet to be well evaluated.

The effects of VNS on neurotransmitter systems show important parallels with current lines of therapeutic investigation in schizophrenia. Ascending projections of the VN terminate in the nucleus tractus solitarius in the medulla, which in turn innervates the locus coeruleus and induces the release of norepinephrine (NE) (49, 50). Activation of adrenergic receptors in the hippocampus can thereby reduce the excitability of the region (51–53). In line with a role for increased adrenergic signaling in the treatment of schizophrenia, adrenergic α2 receptor agonists such as clonidine are currently being investigated in early phase trials in patients. Preliminary studies have demonstrated that activation of this receptor improves sensorimotor (54) and auditory gating (55) deficits in the disease. Guanfacine, an α2A receptor-specific agonist, also shows pro-cognitive effects in several patient populations including schizophrenia (56–58).

A secondary effect of VNS directly relevant to schizophrenia is to increase cholinergic neurotransmission by NE-induced activation of post synaptic beta and α1 adrenergic receptors in the basal forebrain, leading to increased acetylcholine (ACh) release (59). This increase may help normalize deficits in cholinergic neurotransmission in the disorder driven in large part by a significant reduction in the expression of nicotinic ACh receptors on inhibitory interneurons (11, 12, 60–63). Loss of these receptors is also hypothesized to contribute to hippocampal hyperactivity (10, 11, 62), which may be normalized by nicotinic activation of receptors on inhibitory interneurons (61, 64). In support of this view, nicotine, a nicotinic receptor agonist, reduces hippocampal hyperactivity observed during smooth pursuit eye movement in schizophrenia patients (65, 66). This attempt to “self-medicate” may help explain why the majority of patients smoke cigarettes (67). VNS may be a particularly effective method of potentiating nicotinic signaling as its cholinergic effects are conveyed via increased release of ACh. Relative to other nicotinic agonists (such as nicotine), ACh is more quickly degraded by endogenous enzymes, and is therefore less likely to induce receptor desensitization (68).

A third mechanism by which VNS may affect the neurobiology of schizophrenia is via its ability to increase serotonergic release (69). Increased serotonergic tone may in turn decrease hippocampal hyperexcitability by potentiating GABAergic signaling through activation of several serotonin receptor subtypes, including 5-HT2, 3, and 4 (70–73). Activation of the 5-HT1 serotonin receptor subtype is also associated with hippocampal neurogenesis and has been proposed as a potential mechanism to restore pattern separation (a memory-related hippocampal function) deficits in schizophrenia (74). Furthermore, activation of 5-HT3 receptors may relieve tonic inhibition of ACh release (75), increasing cholinergic tone and restoring hippocampal nicotinic signaling in the illness. How VNS specifically affects activity at these receptor targets and their relationship to cognition and hippocampal activity are important areas for future research.

Vagus nerve stimulation, whether administered by surgical implant or transcutaneous stimulation, is a well-tolerated procedure. Risks associated with the surgery itself are minimal (76). The most common side effects associated with stimulation are hoarseness, dyspnea, and cough. Most of these effects decrease with time (77). Nonetheless, VNS may have more significant risks specific to schizophrenia. Compounds that non-specifically (across all adrenergic receptor subtypes) increase noradrenergic activity, such as amphetamine, are known to induce psychosis in normal subjects (78, 79) and worsen positive symptoms in patients (80). Indeed, VNS itself has been associated with the onset of psychosis in epileptic patients in a limited number of case studies (81). It is possible that schizophrenia patients who are taking antipsychotic medication that participate in a VNS study will require

| Table 1 | Studies that have demonstrated effects of VNS on hippocampal activity |
|---------|-------------------------------------------------|
| **Subject population** | **VNS method** | **Imaging technique** | **Effect on HC** | **Reference** |
|---|---|---|---|---|
| Epilepsy | s-VNS | PET | ↓ | Henry et al. (28) |
| | | PET | ↓ | Henry et al. (29) |
| | | HC depth electrodes | ↓ (epileptiform sharp waves) | Oiegniczak et al. (33) |
| | | SPECT | ↓ | Vonck et al. (31) |
| | | SPECT | ↓ | Van Laere et al. (30) |
| | | SPECT | ↓ | Van Laere et al. (34) |
| | | SPECT | ↓ | Barnes et al. (35) |
| | | PET | ↓ | Henry et al. (36) |
| | | PET | ↓ | Vonck et al. (41) |
| Depression | s-VNS | SPECT | ↓ | Devous (32) |
| | | fMRI | ↓ | Mu et al. (37) |
| | | SPECT | ↓ | Zobel et al. (39) |
| | | PET | n.s. | Pardo et al. (45) |
| | | PET | n.s. | Conway et al. (46) |
| Healthy | t-VNS | fMRI | ↓ | Kraus et al. (40) |
| | | fMRI | ↓ | Kraus et al. (42) |
| | | fMRI | ↓ | Frangos et al. (43) |
| Animal (rat) | s-VNS | PET | ↓ | Dedeurvaere et al. (38) |
| | | in vivo electrophysiology | ↓ | Perez et al. (44) |

fMRI, functional magnetic resonance imaging; HC, hippocampus; n.s., no significant effects; PET, positron emission tomography; rBF, regional blood flow; s-VNS, surgical VNS; SPECT, single-photon emission computed tomography; t-VNS, transcutaneous (non-surgical) VNS.
adjustment of antipsychotic doses in order to preserve clinical efficacy. Previous studies, however, have also observed positive correlations between VN/parasympathetic nervous system dysfunction and positive symptoms, suggesting that VNS may actually improve these symptoms (24, 25). As the interactions between VNS and antipsychotic efficacy in schizophrenia are entirely unknown, studies should make closely monitor core symptoms of the illness associated with acute and chronic VNS treatment.

Despite its potential to improve cognition in schizophrenia, to our knowledge no study has yet examined the clinical or physiological effects of VNS in patients with the disease. Lack of research in this area may be due in large part to the invasive-ness of traditional, surgical VNS. To that end, the advent of t-VNS provides a simple, non-invasive method for examining the acute and chronic effects of stimulation in schizophrenia under various stimuli protocols. The recent discovery of hippocampal hyperactivity as a biomarker for cognitive symptoms in schizophrenia provides a useful mechanism to establish target validation using functional neuroimaging. In regards to VNS, the fact that numerous studies have repeatedly demonstrated that stimulation reduces hippocampal activity in other patient populations suggests that it may have the same effect in schizophrenia. Furthermore, although this article has focused on hippocampal effects, VNS may also improve cognition through other mechanisms, such as neurochemical modulation of the prefrontal cortex (82–84) and/or prefrontal–hippocampal interactions (85). In summary, examination of the potential effects of VNS for cognitive symptoms in schizophrenia may be a promising future research direction.

ACKNOWLEDGMENT

JS is supported in part by National Institutes of Health Fellowship #1F31MH102879-01A1. JT is supported in part by the Brain and Behavior Foundation, the Blowitz-Ridgeway Foundation, VA Grant #5-101-CX000459, and NIH Grants #R01-DK80995, R21-DK102052-01A1, and R01-MH102224-01A1.

REFERENCES

1. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry (1996) 153:321–30. doi:10.1176/ajp.153.3.321
2. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cog-nitive domains and test criteria. Biol Psychiatry (2004) 56:501–7. doi:10.1016/j.biopsych.2004.06.023
3. Torrey EF. Surviving Schizophrenia: A Manual for Families, Patients, and Providers. 5th ed. New York, NY: Harper Collins (2006).
4. Tregellas JR, Smucny J, Harris JG, Maharaah K, Kronberg E, et al. Intrinsic hippocampal activity as a biomarker for cognition and symp-toms in schizophrenia. Am J Psychiatry (2014) 171:549–56. doi:10.1176/appi.ajp.2013.13070981
5. Scofield L, Manka C, Daamen M, Kuhn KU, Maier W, Schild HH, et al. Resting-state perfusion in non-medicated schizophrenic patients: a continuous arterial spin-labeling 3.0-T MR study. Radiology (2010) 256:253–60. doi:10.1148/radiol.10091224
6. Scohel SB, Lewandowski NM, Corcoran CM, Moore H, Brown T, Malaspina D, et al. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry (2009) 66:958–46. doi:10.1001/archgenpsychiatry.2009.115
7. Scobel SA, Chaudhury NH, Khan UA, Panigau B, Stynr MA, Asslani I, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron (2013) 78:81–93. doi:10.1016/j.neuron.2013.02.011
8. Tregellas JR, Davalos BR, Rojas DC, Waldo MC, Gibson L, Wylie K, et al. Increased hemodynamic response in the hippocampus, thalamus and pre-frontal cortex during abnormal sensory gating in schizophrenia. Schizophr Res (2007) 92:262–72. doi:10.1016/j.schres.2006.12.033
9. Tregellas JR, Ellis J, Shatti S, Du YP, Rojas DC. Increased hippocampal, thalamic, and prefrontal hemodynamic response to an urban noise stim-ulor in schizophrenia. Am J Psychiatry (2009) 166:354–60. doi:10.1176/appi.ajp.2008.08030411
10. Tregellas JR. Neuroimaging biomarkers for early drug development in schizophrenia. Biol Psychiatr (2014) 76:111–9. doi:10.1016/j.biopsych.2013.08.025
11. Miwa JM, Freedman R, Laster HA. Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. Neuron (2011) 70:20–33. doi:10.1016/j.neuron.2011.03.014
12. Olincy A, Freedman R. Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the alpha2 nicotinic receptor. Handb Exp Pharmacol (2012) 213:211–32. doi:10.1007/978-3-642-25758-2_8
13. Yakel JL. Nicotinic ACh receptors in the hippocam-pus: role in excitability and plasticity. Nicotine Tob Res (2012) 14:1249–57. doi:10.1093/ntr/ntt091
14. Heckers S, Konradi C. GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophr Res (2014). doi:10.1016/j.schres.2014.09.041
15. George MS, Anton-Jones G. Noninvasive tech-niques for probing neurocircuitry and treating ill-ness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). Neuropsy-chopharmacology (2010) 38:301–16. doi:10.1008/ npp.2009.87
16. George MS, Sackeim HA, Rush AJ, Marangell LB, Nasas Z, Hussain MM, et al. Vagus nerve stimulation: a new tool for brain research and ther-apy. Biol Psychiatry (2000) 47:287–95. doi:10.1016/ S0006-3223(99)00308-X
17. Ventureyra EC. Transcutaneous vagus nerve stim-ulation for partial onset seizure therapy. A new concept. Childs Nerv Syst (2000) 16:101–2. doi:10.1007/ s003810050021
18. Rong PJ, Fang JL, Wang LP, Meng H, Liu J, Ma YG, et al. Transectional vagus nerve stimula-tion for the treatment of depression: a study pro-tocol for a double blinded randomized clinical trial. BMC Complement Altern Med (2012) 12:255. doi:10.1186/1472-6882-12-255
19. Stefan H, Kreiselmeyer G, Keflir F, Kurzbuch B, Rauch C, Heers M, et al. Transectional vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: a proof of concept trial. Epilepsia (2012) 53:e115–8. doi:10.1111/j.1528-1353.2012.00349.x
20. He W, Wang X, Shi H, Shang H, Li L, Jing X, et al. Auricular acupuncture and vagal regula-tion. Evid Based Complement Alternat Med (2012) 2012:768659. doi:10.1155/2012/768659
21. Malaspina D, Bruder G, Dalack GW, Storer S, Van Kammen M, Amador X, et al. Diminished cardiac vagal tone in schizophrenia: associations to brain laterality and age of onset. Biol Psychiatry (1997) 41:612–7. doi:10.1016/s0006-3223(96)00161-8
22. Bar KJ, Leitzsch A, Kochum T, Wagner G, Greiter W, Sauer H. Loss of effector vagal activity in acute schizophrenia. J Psychiatr Res (2005) 39:519–27. doi:10.1016/j.jpsychires.2004.12.007
23. Boettger S, Hoyer D, Falkenhahn K, Kaatz M, Yeragani VK, Bar KJ. Altered diurnal autonomic variation and reduced vagal information flow in acute schizophrenia. Clin Neurophysiol (2006) 117:2715–22. doi:10.1016/j.clinph.2006.08.009
24. Bar KJ, Wernich K, Boettger S, Cordes J, Boettger MK, Loffler S, et al. Relationship between cardiovascular modulation and psychotic state in patients with paranoid schizophrenia. Psychia-try Res (2008) 157:255–7. doi:10.1016/j.psychres.2007.04.021
25. Bar KJ, Rachow T, Schulz S, Bassarab K, Haufe S, Berger S, et al. The phrenic component of acute schizophrenia – a name and its physiologi-cal reality. PLoS One (2012) 7:e33459. doi:10.1371/journal.pone.0033459
26. Ostermann S, Herbsleb M, Schulz S, Donath L, Berger S, Eisentrager D, et al. Exercise reveals the interrelation of physical fitness, inflammatory response, psychopathology, and autonomic func-tion in patients with schizophrenia. Schizophr Bull (2013) 39:1139–49. doi:10.1093/schbul/bst085
27. Capone F, Assenza G, Di Pino G, Musumeci G, Ranieri F, Florio L, et al. The effect of transectional vagus nerve stimulation on cortical excitability. J Neurophysiol (2014). doi:10.1152/jn-00702-014-1299-7
28. Henry TR, Bakay RA, Votaw JR, Pennell PB, Epstein CM, Faber TL, et al. Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimulation. Epilepsia (1998) 39:983–90. doi:10.1111/j.1528-1157.1998.tb14448.x
involvement in the mechanism of action of vagus nerve stimulation, a SPECT study. Seizure (2008) 17:699–706. doi:10.1016/j.seizure.2008.05.001
42. Kraus T, Kiess O, Hodi K, Terekhin P, Kornhuber J, Forster C. CNS BOLD fMRI effects of sham-controlled transcutaneous electrical nerve stimulation in the left outer auditory canal – a pilot study. Brain Stimul (2013) 6:798–804. doi:10.1016/j.brs.2013.01.011
43. Frangos E, Ehrlich J, Komissaruk BR. Non-invasive access to the vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans. Brain Stimul (2014). doi:10.1016/j.brs.2014.11.018
44. Perez SM, Carreno FR, Frazer A, Lodge DJ. Vagal nerve stimulation reverses aberrant dopamine system function in the methylyazoxymethanol acetate rodent model of schizophrenia. J Neuropsychiatry Clin Neurosci (2013) 24:926–7. doi:10.1523/JNEUROCSCI.0588-14.2014
45. Pardo IV, Sheikh SA, Shwicdt GC, Lee JT, Kuskowski MA, Surerus C, et al. Chronic vagus nerve stimulation for treatment-resistant depression: decreasing resting ventromedial prefrontal glucose metabolism. Neuroimage (2008) 42:879–89. doi:10.1016/j.neuroimage.2008.04.267
46. Conway CR, Sheline YI, Chauhall JT, Buchholz RD, Price JL, Gangwani S, et al. Brain blood-flow change with acute vagus nerve stimulation in treatment-refractory major depressive disorder. Brain Stimul (2012) 5:163–71. doi:10.1016/j.brs.2011.03.001
47. Perez SM, Shah A, Asher A, Lodge DJ. Hippocampal deep brain stimulation reverses physiological and behavioural deficits in a rodent model of schizophrenia. Int J Neuropsychopharmacol (2013) 16:1331–9. doi:10.1017/S1117514913001344
48. Vonck K, Raedt R, Naulaerts J, De Vogelaere F, De Herdt V, Bosman T, et al. The effect of vagus nerve stimulation in rats: a pilot study. Eur J Nucl Med Mol Imaging (2000) 120:873–4. doi:10.1007/s00259-000-01356-3
49. Van Bockstaele EJ, Peoples J, T elegan P. Efferent projections of the nucleus of the solitary tract to peri-locus coeruleus dendrites in rat brain: evidence for a monosynaptic pathway. J Comp Neurol (1999) 412:410–28. doi:10.1002/(SICI)1096-9811(19990221)412:4<412::AID-CNE3>3.0.CO;2-F
50. Van Bockstaele EI, Peoples J, Valention BJ, AE. Bennett research award. Anatomical basis for differential regulation of the rostraltral peri-locus coeruleus region by limbic afferents. Biol Psychiatry (1999) 46:1352–63. doi:10.1016/S0006-3223(99)00213-9
51. Jurgens CW, Hammad HM, Lichter JA, Boese SJ, Nelson BW, Goldenstein BL, et al. Alpha2A adrenergic receptor activation inhibits epileptiform activity in the rat hippocampal CA3 region. Mol Pharmacol (2007) 71:1527–81. doi:10.1124/mol.106.031773
52. Hildeman KL, Lei S, Doze VA, Porter JE. Alpha-1A adrenergic receptor activation increases inhibitory tone in Ca1 hippocampus. Epilepsia (2009) 50:847–9. doi:10.1111/j.1528-1157.2008.01283.x
53. Lipski WJ, Grace AA. Activation and inhibition of neurons in the hippocampal ventral subiculum by norepinephrine and locus coeruleus stimulation. Neuropsychopharmacology (2013) 38:285–92. doi:10.1038/npp.2012.157
54. Oranje B, Glenthoj BY. Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication. Schizophr Bull (2013) 39:684–91. doi:10.1093/schbul/sbs071
55. Oranje B, Glenthoj BY. Clonidine normalizes levels of P50 gating in patients with schizophrenia on stable medication. Schizophr Bull (2014) 40:1022–9. doi:10.1093/schbul/sbu144
56. Friedman JJ, Adler DN, Temporini HD, Kemether E, Harvey PD, White L, et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology (2001) 25:402–9. doi:10.1016/S0893-133X(01)00249-4
57. Ruggiero S, Clavenna A, Reale L, Capuano A, Rossi F, Bonati M. Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis. Eur Neuropsychopharmacol (2014) 24:1578–90. doi:10.1016/j.euroneuro.2014.08.001
58. Fox H, Sofouglou M, Sinha R. Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals. J Psychopharmacol (2015) 29:3:312–23. doi:10.1177/1359022814556246
59. Port P, Khatib A, Pegna A, Muhlheuter M, Jones BE. Noradrenergic modulation of cholinergic nucleus basalis neurons demonstrated by in vitro pharmacological and immunohistochemical evidence in the guinea-pig brain. J Neurol Neurosurg Psychiatry (1995) 5:1502–11. doi:10.1136/jn.5:5:1958-9955.1995.00814.x
60. Freedman R, Hall M, Adler LE, Leonard S. Evid- ence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry (1995) 38:22–33. doi:10.1016/0006-3223(94)00252-X
61. Frazier CJ, Rolls YD, Breese CR, Leonard S, Freedman R, Dunwiddie TV. Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci (1998) 18:1187–95.
62. Freedman R, Adams CE, Leonard S. The alpha-7 nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanat (2000) 20:299–306. doi:10.1016/S0891-6188(00)00109-5
63. Leonard S, Breese C, Adams C, Benhammou K, Gault J, Stevens K, et al. Smoking and schizo- phrenia: abnormal nicotinic receptor expression. Eur J Pharmacol (2003) 393:237–42. doi:10.1016/S0014-2999(03)00005-2
64. Szabo GG, Holdenhert N, Gulyas AI, Freund TF, Hajos N. Distinct synaptic properties of perisynaptic inhibitory cell types and their different modula- tion by cholinergic receptor activation in the CA3 region of the mouse hippocampus. J Neurosci (2010) 31:2324–46. doi:10.1523/JNEUROSCI.1160-09.2010.07292.x
65. Tregellas JR, Tanabe JL, Martin LF, Freedman R, FMRI of response to nicotine during a smooth pursuit eye movement task in schizophrenia. Am J Psychiatry (2005) 162:391–3. doi:10.1176/appi.ae.162.2.391
66. Tanabe J, Tregellas JR, Martin LF, Freedman R. Effects of nicotine on hippocampal and cingulate...
activity during smooth pursuit eye movement in schizophrenia. *Biol Psychiatry* (2006) 59:754–61. doi:10.1016/j.biopsych.2005.09.004
67. Winterer G. Why do patients with schizophrenia smoke? *Curr Opin Psychiatry* (2010) 23:112–9. doi:10.1097/YCO.0b013e3283366643
68. Papke RL. Merging old and new perspectives on nicotinic acetylcholine receptors. *Biochem Pharmacol* (2014) 89:1–11. doi:10.1016/j.bcp.2014.01.029
69. Dorr AE, Debonnel G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. *J Pharmacol Exp Ther* (2006) 318:890–8. doi:10.1124/jpet.106.104166
70. Ropert N, Guy N. Serotonin facilitates GABAergic neurotransmission. *J Neurochem* (2007) 103:2342–53. doi:10.1111/j.1471-4159.2007.04945.x
71. Shen RY, Andrade R. 5-Hydroxytryptamine2 receptors partial agonist, and an antagonist. *Neuropharmacology* (2004) 47:1021–35. doi:10.1016/j.neuropharm.2004.06.033
72. Marchetti E, Chaillan FA, Dumuis A, Bockaert J, Sackeim HA, Rush AJ, George MS, Marangell LB, Husain MM, Nahas Z, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. *Neuropsychopharmacology* (2001) 25:713–28. doi:10.1016/S0893-133X(01)00271-8
73. Sackeim HA, Rush AI, George MS, Marangell LB, Husain MM, Nahas Z, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. *Neuropsychopharmacology* (2001) 25:713–28. doi:10.1016/S0893-133X(01)00271-8
74. Angrist B, Corwin J, Bartlik B, Cooper T. Early dopaminoceptors and clinical effects of oral D-amphetamine in normal subjects. *Biol Psychiatry* (1987) 22:1357–68. doi:10.1016/0006-3223(87)90070-9
75. Grant KM, Levan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, et al. Methamphetamine-associated psychoses. *J Neuroimmune Pharmacol* (2012) 7:113–39. doi:10.1007/s11481-011-9288-1
76. Curran C, Byrappa N, Mcbride A. Stimulant psychoses: systematic review. *Br J Psychiatry* (2004) 185:196–204. doi:10.1192/bjp.185.3.196
77. de Herdt V, Boon P, Vonck K, Goossens L, Sarter M. Modulators in concert for cognition: to the brainstem and beyond. *Psychiatry (Edgerton)* (2006) 3:54–63.
78. Angrist B, Corwin J, Bartlik B, Cooper T. Early dopaminoceptors and clinical effects of oral D-amphetamine in normal subjects. *Biol Psychiatry* (1987) 22:1357–68. doi:10.1016/0006-3223(87)90070-9
79. Grant KM, Levan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, et al. Methamphetamine-associated psychoses. *J Neuroimmune Pharmacol* (2012) 7:113–39. doi:10.1007/s11481-011-9288-1
80. Carran C, Byrappa N, Mcbride A. Stimulant psychoses: systematic review. *Br J Psychiatry* (2004) 185:196–204. doi:10.1192/bjp.185.3.196
81. Shirazi-Southall S, Rodriguez DE, Nomikos GG. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. *Neuropsychopharmacology* (2002) 26:583–94. doi:10.1016/S0893-133X(01)00400-6
82. O’Reardon JP, Cristancho P, Peshek AD. Vagus nerve stimulation (VNS) and treatment of depression: to the brainstem and beyond. *Psychiatry (Edgerton)* (2006) 3:54–63.
83. Sackeim HA, Rush AI, George MS, Marangell LB, Husain MM, Nahas Z, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. *Neuropsychopharmacology* (2001) 25:713–28. doi:10.1016/S0893-133X(01)00271-8
84. Potkin SG, Turner JA, Brown GG, McCarthvy G, Greve DN, Glover GH, et al. Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. *Schizophr Bull* (2009) 35:19–31. doi:10.1093/schbul/bsn162
85. Sigurdsson T, Stark KL, Karayiorgou M, Gogos JA, Gordon JA. Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. *Nature* (2010) 464:763–7. doi:10.1038/ nature08855

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 21 January 2015; accepted: 10 March 2015; published online: 24 March 2015.

Citation: Smucny J, Visani A and Tregellas JR (2015) Could vagus nerve stimulation target hippocampal hyperactivity to improve cognition in schizophrenia? *Front Psychol* 6:43. doi: 10.3389/fpsyg.2015.00043
This article was submitted to Neuropsychiatric Imaging and Stimulation, a section of the journal Frontiers in Psychiatry. Copyright © 2015 Smucny, Visani and Tregellas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these terms.